Health Canada is currently assessing nine submissions for generic versions of well-known weight loss medications, a move that experts believe could potentially reduce costs. These submissions are for generic variants of semaglutide, the key component in Novo Nordisk’s injectable drugs Ozempic and Wegovy, approved by Health Canada for treating diabetes and aiding in weight loss. Semaglutide falls under the category of glucagon-like peptide-1 (GLP-1) therapies, which mimic a natural gut hormone to regulate blood sugar, slow digestion, and promote satiety. Typical side effects of semaglutide may include nausea, vomiting, diarrhea, stomach pain, fatigue, constipation, and headaches.
Canada stands out as the sole country where Novo Nordisk’s patent for semaglutide drugs has expired, leading to the end of “regulatory exclusivity” on Jan. 4. Consequently, Canada could potentially be the first nation to offer more budget-friendly alternatives to Ozempic and Wegovy, though immediate availability is unlikely, according to pharmaceutical experts. The approval status and pricing details of these drugs are under review.
Wegovy, a pill form of Novo Nordisk’s weight loss drug, has recently been introduced in the U.S. with plans for higher dosages to be accessible shortly. While the availability of Wegovy in Canada remains unclear, Health Canada has not confirmed if they have received an application for the pill form of Wegovy or its generic equivalent.
Generics, which are equivalent to brand name drugs, undergo thorough evaluation by Health Canada to ensure they meet safety, quality, and effectiveness standards. The development of generic semaglutide drugs poses unique challenges due to their complex nature compared to standard medication approvals. Pricing for generics is influenced by various factors, including the drug’s formulation, dosage, and market competition.
While the introduction of cheaper alternatives holds promise for reducing costs, challenges in the approval process may delay immediate availability. Experts anticipate that more affordable versions could potentially be accessible by the summer, offering relief to Canadians who currently bear the financial burden of weight loss medications. Access to generics could enhance obesity management by providing cost-effective solutions for patients who lack insurance coverage for these essential medications. Several pharmaceutical companies, including Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, and Aspen Pharmacare Canada, have submitted generic versions for review by Health Canada.